Brochure More information from

Transcription

1 Brochure More information from Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM Description: This report provides in-depth analysis of the Glioblastoma Multiforme (GBM) therapeutics market within the Asia-Pacific (APAC) region, covering Australia, China, India and Japan. The report provides estimates of market size for 2013, along with market forecasts until It also covers disease epidemiology, treatment algorithms, treatment patterns, and in-depth analysis of the marketed and pipeline products. The value of the GBM market in the APAC region amounted to an estimated $49.4m in 2013, and is expected to register a Compound Annual Growth Rate (CAGR) of 11.5%, to reach $105.8m by The GBM market in India was the smallest of the APAC markets in 2013, but is expected to experience the highest growth rate in the forecast period, at a CAGR of 14.4%, due to having the highest number of promising candidates in the pipeline. Japan currently has the largest share of GBM market in the APAC region, at 48%, and is expected to experience healthy growth during the forecast period at a CAGR of 13.8%. The existing treatment landscape is bleak for both newly diagnosed and recurrent GBM, with temozolomide alone serving as the standard of care after surgery and radiation. For first-line treatment Rindopepimut, a novel vaccine, is in late-stage development in India and Australia, but it is limited to EGFRvIII patients. There are two strong candidates in the current pipeline for second-line treatment: Avastin and Cotara. Avastin is the first and only targeted therapy for newly diagnosed GBM, is already approved as second-line treatment in Australia and Japan, and is in Phase III development in China and India. Cotara is a single-infusion drug with a novel delivery route, which is in Phase II development in India. The expected launch of these three drugs is the key driver for growth in APAC GBM market. As all are expensive, even a modest uptake will increase the annual cost of therapy, and subsequently the market size. Scope: - A brief introduction to GBM, including disease pathogenesis, risk factors, diagnosis, treatment options and algorithm - In-depth analysis of major marketed products, covering product performance, life-cycle, and a heat map depicting comparative analysis of safety and efficacy parameters - A comprehensive review of the GBM pipeline including individual analysis of promising late-stage pipeline drugs that are likely to enter the market during the forecast period analyzed on the basis of phase distribution, molecule types and molecular targets - Additional clinical trial analysis by phase, trial size, trial duration and program failure rate analyses, for each molecule type and mechanism of action - Multi-scenario forecasts of the GBM market from 2013 to 2020 in the four APAC countries - An overview of key licensing and co-development agreements that could have an impact on growth trends - Analysis of the key drivers and restraints that have had and are expected to have a significant impact on the market Reasons to purchase: - Align your product portfolio to the markets with high growth potential - Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth - Devise a more effectively tailored strategy through the understanding of key drivers and barriers in the GBM market - Develop key strategic initiatives based on an understanding of key focus areas and leading companies - Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships Contents: 1.1 List of Tables 1.2 List of Figures

2 2 Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to Introduction 2.1 Disease Introduction 2.2 Classification of Brain Tumors 2.3 Tumor Grading 2.4 Subtypes of Glioblastoma Multiforme 2.5 Etiology 2.6 Pathophysiology Loss of Heterozygosity of Chromosome Epidermal Growth Factor Receptor Amplification Phosphatase and Tensin Homolog Mutation Loss of p53 Function p16ink4a Alteration and Loss of Normal Retinoblastoma 1 Function Isocitrate Dehydrogenase 1 or Isocitrate Dehydrogenase 2 Mutation 2.7 Symptoms 2.8 Diagnosis 2.9 Prognosis 2.10 Epidemiology 2.11 Treatment Options Surgery Radiation Therapy Chemotherapy Targeted Therapy Drugs for Symptom Relief Other Alternative Therapies 2.12 Treatment Algorithm 3 Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to Marketed Products 3.1 Key Marketed Products 3.2 Temodar (temozolomide) - Merck 3.3 Avastin (bevacizumab) - Roche 3.4 BiCNU (carmustine) and Gliadel Wafer (carmustine in polifeprosan) BiCNU (carmustine) - Bristol-Myers Squibb Gliadel Wafer (carmustine in polifeprosan) - Eisai 3.5 Unlicensed/Off-Label Use in Glioblastoma Multiforme Lomustine Carboplatin Teniposide 3.6 Comparative Efficacy and Safety 3.7 Unmet Needs 4 Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to Pipeline 4.1 Overall Pipeline 4.2 Molecular Targets 4.3 Clinical Trials Clinical Trial Size Clinical Trial Duration Failure Rate of Developmental Pipeline Summary of Clinical Trial and Risk Analysis 4.4 Promising Pipeline Candidates Rindopepimut (CDX-110) - Celldex Therapeutics Avastin (bevacizumab) - Roche Cotara - Peregrine Pharmaceuticals BIOMAb (nimotuzumab) - BioCon 4.5 Heat Map of Safety and Efficacy and Product Competitiveness Framework for Glioblastoma Multiforme Pipeline 5 Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to Market Forecast to Asia-Pacific Market Treatment Use Patterns Market Size 5.2 Australia Treatment Use Patterns

3 5.2.2 Annual Cost of Therapy Market Size 5.3 China Treatment Use Patterns Annual Cost of Therapy Market Size 5.4 India Treatment Use Patterns Annual Cost of Therapy Market Size 5.5 Japan Treatment Use Patterns Annual Cost of Therapy Market Size 5.6 Drivers and Barriers for the Glioblastoma Multiforme Therapeutics in the Asia-Pacific Market to Drivers Barriers 6 Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to Deals and Strategic Consolidations 6.1 Major Co-Development Deals Del Mar Pharmaceuticals Enters into Agreement with Guangxi Wuzhou Pharmaceutical Immatics Biotechnologies Enters into Agreement with Cancer Research UK 6.2 Major Licensing Deals Eisai Received Marketing Authorization Holder License with Nobelpharma for Gliadel in Japan Teva Pharma Enters into Agreement with Perrigo for Generic Temozolomide SOM Biotech Enters into Licensing Agreement with Argon Pharma for SOM ImmunoCellular Therapeutics Enters into Agreement with University of Pennsylvania Bexion Pharmaceuticals Enters into Agreement with Cincinnati Children s Hospital Medical Center Celldex Therapeutics Enters into Agreement with Duke University Brain Tumor Cancer Center 7 Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to Appendix 7.1 Market Definitions 7.2 Abbreviations 7.3 Bibliography 7.4 All Pipeline Products by Phase Discovery Preclinical Phase I Phase II Phase III and Pre-Registration Undisclosed stage of development 7.5 Market Forecasts to Asia-Pacific Australia China India Japan 7.6 Research Methodology Coverage Secondary Research Therapeutic Landscape Forecasting Geographical Landscape Pipeline Analysis 7.7 Competitive Landscape 7.8 Expert Panel Validation 7.9 Contact Us 7.10 Disclaimer 1.1 List of Tables: Table 1: Glioblastoma Multiforme, Classification of Brain Tumors by the American Association of Neurological Surgeons, 2014

4 Table 2: Glioblastoma Multiforme, World Health Organization Classification of Glioma, 2005 Table 3: Glioblastoma Multiforme, Karnofsky Performance Status Score (%), 1984 Table 4: Discovery Table 5: Preclinical and IND/CTA-filed Table 6: Phase I Table 7: Phase II Table 8: Phase III and pre-registration Table 9: Undisclosed stage of development Table 10: Glioblastoma Multiforme Therapeutics, Asia-Pacific, Forecast Data, Table 11: Glioblastoma Multiforme Therapeutics, Australia, Forecast Data, Table 12: Glioblastoma Multiforme Therapeutics, China, Forecast Data, Table 13: Glioblastoma Multiforme Therapeutics, India, Forecast Data, Table 14: Glioblastoma Multiforme Therapeutics, Japan, Forecast Data, List of Figures: Figure 1: Glioblastoma Multiforme, Genetic Pathways to Primary and Secondary GBM and the Incidence of Mutations, 2014 Figure 2: Glioblastoma Multiforme, Treatment Algorithm for Glioblastoma Multiforme, 2014 Figure 3: Glioblastoma Multiforme, Treatment Options for Recurrent Glioblastoma Multiforme, 2014 Figure 4: Glioblastoma Multiforme, Global, Historical Sales of Temodar ($m), Figure 5: Glioblastoma Multiforme, Global, Historical Sales of Avastin ($bn), Figure 6: Glioblastoma Multiforme, Global, Historical Sales of Gliadel Wafer ($m), Figure 7: Glioblastoma Multiforme, Global, Heat Map for Marketed Products, 2013 Figure 8: Glioblastoma Multiforme, Global, Overall Pipeline, 2013 Figure 9: Glioblastoma Multiforme, Global, Program Type by Phase and Molecular Targets, 2013 Figure 10: Glioblastoma Multiforme, Global, Mean Clinical Trial Size by Molecule Type, Figure 11: Glioblastoma Multiforme, Global, Mean Clinical Trial Duration by Molecule Type (Months), Figure 12: Glioblastoma Multiforme, Global, Clinical Trial Failure Rate by Phase by Molecule Type and Reasons for Failure, Figure 13: Glioblastoma Multiforme, Asia-Pacific, Heat Map for Pipeline Products, 2013 Figure 14: Glioblastoma Multiforme, Asia-Pacific, Product Competitiveness Framework, 2013 Figure 15: Glioblastoma Multiforme Therapeutics, Asia-Pacific, Treatment Use Patterns ( 000), Figure 16: Glioblastoma Multiforme Therapeutics, Asia-Pacific, Market Size ($m), Figure 17: Glioblastoma Multiforme Therapeutics, Australia, Treatment Use Patterns ( 000), Figure 18: Glioblastoma Multiforme Therapeutics, Australia, Annual Cost of Therapy ($), Figure 19: Glioblastoma Multiforme Therapeutics, Australia, Market Size ($m), Figure 20: Glioblastoma Multiforme Therapeutics, China, Treatment Use Patterns ( 000), Figure 21: Glioblastoma Multiforme Therapeutics, China, Annual Cost of Therapy ($), Figure 22: Glioblastoma Multiforme Therapeutics, China, Market Size ($m), Figure 23: Glioblastoma Multiforme Therapeutics, India, Treatment Use Patterns ( 000), Figure 24: Glioblastoma Multiforme Therapeutics, India, Annual Cost of Therapy ($), Figure 25: Glioblastoma Multiforme Therapeutics, India, Market Size ($m), Figure 26: Glioblastoma Multiforme Therapeutics, Japan, Treatment Use Patterns ( 000), Figure 27: Glioblastoma Multiforme Therapeutics, Japan, Annual Cost of Therapy ($), Figure 28: Glioblastoma Multiforme Therapeutics, Japan, Market Size ($m), Ordering: Order Online - Order by Fax - using the form below Order by Post - print the order form below and send to Research and Markets, Guinness Centre, Taylors Lane, Dublin 8, Ireland.

5

6 Page 1 of 2 Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to (from USA) or (from Rest of World). If you have any questions please visit Order Information Please verify that the product information is correct and select the format(s) you require. Product Name: Web Address: Office Code: Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM SC Product Formats Please select the product formats and quantity you require: Electronic (PDF) - Single User: Electronic (PDF) - Site License: Electronic (PDF) - Enterprisewide: Quantity USD 4995 USD 9990 USD * The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change. Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: Last Name: Address: * Job Title: Organisation: Address: City: Postal / Zip Code: Country: Phone Number: Fax Number: * Please refrain from using free accounts when ordering (e.g. Yahoo, Hotmail, AOL)

7 Page 2 of 2 Payment Information Please indicate the payment method you would like to use by selecting the appropriate box. Pay by credit card: You will receive an with a link to a secure webpage to enter your credit card details. Pay by check: Please post the check, accompanied by this form, to: Research and Markets, Guinness Center, Taylors Lane, Dublin 8, Ireland. Pay by wire transfer: Please transfer funds to: Account number Sort code Swift code IBAN number Bank Address ULSBIE2D IE78ULSB Ulster Bank, Main Street, Blackrock, Co. Dublin, Ireland. If you have a Marketing Code please enter it below: Marketing Code: Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at Please fax this form to: (646) or (646) From USA or From Rest of World